Jefferies Upgrades Vistagen Therapeutics to Buy, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Andrew Tsai has upgraded Vistagen Therapeutics (NASDAQ: VTGN) from Hold to Buy and significantly increased the price target from $0.2 to $15.
December 07, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics has been upgraded by Jefferies from Hold to Buy, with a price target increase from $0.2 to $15, indicating a positive outlook on the stock.
The upgrade from Hold to Buy by a reputable analyst at Jefferies, along with a substantial increase in the price target, suggests a strong bullish sentiment on Vistagen Therapeutics. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price as the market reacts to the new information.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100